Alkermes plc Stock Price and Value Analysis

Alkermes plc (NasdaqGS:ALKS) in our automated value investing analysis, with the cash flow history and price comparison below.

Key Facts

Advertisement helps keep Trendshare free for most readers.

Hold-time calculator

Estimate how long you need to hold Alkermes plc to reach your target.

Target type

ALKS Free Cash Flow Trend

Free Cash Flow trendline for ALKS
Free Cash Flow trendline for Alkermes plc
CSV

Based on historical returns, we believe that Alkermes plc can grow its free cash at a rate of about 4%. That's positive!

AdvantagesDisadvantagesNeutral
  • This company is solid.
  • This company is making money at a modest rate.
  • This company has wild ups and downs.
  • This stock looks overpriced.
  • This company pays no dividend.

Inside the ALKS Numbers

ALKS Price
(Alkermes plc stock price per share)
$44.94
[?] ALKS Fair Price
(based on intrinsic value)
$10.83
[?] ALKS Safety Price (based on a variable margin of safety) $7.04
Try your own return

The fair price above uses a 10.1% discount rate, the long-run US stock return (10.1% geometric, 1926 to 2025, from Bessembinder's working paper, updated 2026-11-09), and 2.5% terminal growth. A higher rate suits a higher return target and gives a lower value.

Value per share:

[?] PE Ratio versus Sector 506% higher than other Healthcare stocks
[?] PE Ratio versus Industry 180% higher than other Drug Manufacturers - General stocks
[?] Cash Yield 1.47%
[?] Free Cash Flow Jitter 168%

Insider Activity Summary

No open-market insider buys or sells are recorded for the last 12 months.

This stock has short interest! This means that people have shorted it.

Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.

As of the latest analysis, there are 19,647,994 shares shorted. With 155,475,564 shares available for purchase and an average trading volume over the past 10 trading days of 1,480,470, it would take at least 13.3 days for all of the short holders to cover their shorts.

What does this mean to you? At this volume, it'll take more than two trading weeks for shorts to cover. This may indicate a short squeeze play would work! If this stock has good fundamentals and it'll take a while for the short holders to cover, buying now could net you bigger short-term technical gains if and as the price rises.

Related guides: good annual rate of return · high-yield stocks · forecasting earnings growth

Free Cash Flow by Fiscal Year

How to read this: free cash flow in plain terms, free cash flow jitter.

Each year names the SEC filer that reported it, so a change of filer shows up here.

Fiscal yearSEC filer (CIK)Free cash flow (USD millions)
2010 1520262 -28
2011 1520262 -18.5
2012 1520262 -16.5
2013 1520262 131
2014 1520262 -8.5
2015 1520262 -67.4
2016 1520262 -97.7
2017 1520262 -21.6
2018 1520262 49.1
2019 1520262 10.4
2020 1520262 23.3
2021 1520262 45.3
2022 1520262 -32.7
2023 1520262 352
2024 1520262 401
2025 1520262 483

Download the yearly data as CSV.

Cash Conversion

How to read this: what free cash flow is, why earnings matter.

Over the 4 fiscal years from 2010 to 2025 with positive net income, operating cash flow totaled $1,509 million against net income of $989 million, or 1.52 times. Net income was negative in 12 of the 16 years, and those years are left out of the ratio.

In 2025, capital expenditures were $40.4 million, 7.8% of operating cash flow of $521 million, which leaves an estimated $480 million after capex. Across the 11 years with reported capex, it averaged 26.0% of operating cash flow. This uses that year's own capital expenditures, not the five-year average behind the free cash flow table, so the two can differ.

Fiscal yearNet income (USD millions)Operating cash flow (USD millions)Capital expenditures (USD millions)Operating cash flow / net income
2010 -39.6 -12.2 15.8 n/a
2011 -45.5 -5.9 9.4 n/a
2012 -114 -2.5 17 n/a
2013 25 148 22.2 5.91
2014 -30.1 11.1 33.7 n/a
2015 -227 -40.4 52.9 n/a
2016 -208 -63.8 43.7 n/a
2017 -158 19.2 51.3 n/a
2018 -139 99.3 69.4 n/a
2019 -197 72.1 90.9 n/a
2020 -111 82.8 42.2 n/a
2021 -48.2 102 28 n/a
2022 -158 21 38.3 n/a
2023 356 401 48 1.13
2024 367 439 33.5 1.20
2025 242 521 40.4 2.15

Revenue and Cash Margin

How to read this: earnings and margins.

Revenue was $178 million in 2010 and $1,476 million in 2025, a compound annual growth rate of 15.1% over 15 years.

Revenue fell 5.2% from 2024 to 2025.

Our estimated free cash flow was $483 million in 2025, 32.7% of revenue. In 2010 the estimated margin was negative 15.7%. This estimate charges each year with the average of up to five years of capital expenditures, so it is not the free cash flow the company reported.

Fiscal yearRevenue (USD millions)Estimated free cash flow (USD millions)Estimated free cash flow / revenue
2010 178 -28 -15.7%
2011 187 -18.5 -9.9%
2012 390 -16.5 -4.2%
2013 596 131 22.0%
2014 619 -8.5 -1.4%
2015 628 -67.4 -10.7%
2016 746 -97.7 -13.1%
2017 903 -21.6 -2.4%
2018 1,094 49.1 4.5%
2019 1,171 10.4 0.9%
2020 1,039 23.3 2.2%
2021 1,174 45.3 3.9%
2022 1,112 -32.7 -2.9%
2023 1,663 352 21.2%
2024 1,558 401 25.8%
2025 1,476 483 32.7%

Balance Sheet

How to read this: how debt and assets are compared, the current ratio.

In 2025, cash and equivalents were $389 million against total liabilities of $668 million, or 58.2% of total liabilities. Total liabilities include everything the company owes, not only borrowed money.

Total liabilities were 26.8% of total assets in 2025, compared with 13.4% in 2011, an increase of 13.5 percentage points.

Stockholders equity was $1,819 million in 2025, compared with $392 million in 2011, a rise of 364.1%.

Based on our estimated free cash flow, cash flow return on invested capital (CROIC) was 31.1% in 2025. Invested capital here is total assets less cash and current liabilities.

Fiscal yearTotal assets (USD millions)Cash and equivalents (USD millions)Total liabilities (USD millions)Stockholders equity (USD millions)
2011 452 38.4 60.4 392
2012 1,435 83.6 581 854
2013 1,578 168 512 1,065
2014 1,919 224 522 1,397
2015 1,856 181 541 1,314
2016 1,726 186 517 1,209
2017 1,797 191 594 1,203
2018 1,825 267 654 1,171
2019 1,805 204 720 1,085
2020 1,950 273 883 1,067
2021 2,024 338 912 1,113
2022 1,964 292 920 1,044
2023 2,136 457 934 1,203
2024 2,056 291 591 1,465
2025 2,487 389 668 1,819

Price Versus Our Estimated Value

Free cash flow was positive in 8 out of 16 reported years for Alkermes plc, using only its current SEC filer.

Free cash flow is volatile from year to year, with a variability measure of 168%.

At $44.94, the price is above our fair value estimate of $10.83 for Alkermes plc.

Dividends are not in our data for Alkermes plc.

Our value investing guide explains how to test these numbers against the filings themselves.

Compared With Its Sector and Industry

How to read this: the price to earnings ratio.

Its trailing P/E ratio is 506% above the average for stocks in the Healthcare sector.

Its trailing P/E ratio is 180% above the average for stocks in the Drug Manufacturers - General industry.

A P/E ratio depends on trailing earnings, which one-time items can distort, so a lower P/E is not by itself evidence of value.

Closest Industry Peers

These are companies in the Drug Manufacturers - General industry, the ones closest in market capitalization to Alkermes plc, limited to companies whose pages we publish. The figures come from our latest data for each company.

CompanyMarket cap (USD millions)P/EDividend yieldCash yieldPrice versus our estimate
Alkermes plc (ALKS) 7,552 - - 1.5% 315% above
Corcept Therapeutics Incorporated (CORT) 7,112 48.9 - 0.0% 858% above
Prestige Consumer Healthcare (PBH) 2,352 15.3 - 7.8% 50% below
Elanco Animal Health Incorporated (ELAN) 12,866 - - - 96% above
Perrigo Company plc (PRGO) 2,213 - 7.2% 72.9% 91% below
ANI Pharmaceuticals (ANIP) 1,558 13.9 - - 188% above
Phibro Animal Health Corporation (PAHC) 1,352 13.9 1.4% - 82% above

Industry labels are approximate, and companies in one industry can run quite different businesses, so a peer may not be a close match.

Ratios on different fiscal calendars are not strictly comparable, and a trailing P/E can be distorted by one-time items.

SEC Filer History

Every fiscal year on this page is reported by one SEC filer, CIK 1520262.

Each figure on this page comes from that filer.

Risks to This Analysis

How to read this: understanding investment risk.

  • Free cash flow was negative in 8 of the 16 years we have.
  • Free cash flow is volatile from year to year, so the estimates depend heavily on which years are included.
  • These figures are automated calculations from SEC filings and the recent price. They may contain errors, and they do not reflect lawsuits, management changes, or other events the filings do not show.

How This Page Is Made

Latest annual report used
Fiscal year 2025
Price and market data last refreshed
2026-11-20
Model assumptions last reviewed
2026-11-09

Company figures come from the annual reports (Form 10-K) that each company files with the SEC, read from the SEC EDGAR company facts data. The share price and other market data come from a market data provider.

Free cash flow here is operating cash flow minus capital spending. To keep one unusual year from swinging the result, each year is charged with the average of up to five years of capital spending, so the figure is an estimate and not the free cash flow a company reports.

The fair price is the present value of ten years of projected free cash flow plus a terminal value, discounted at 10.1 percent a year, the long-run return of US stocks, with 2.5 percent growth after year ten. The figures on this page are estimates, not advice.

This analysis covers US companies that file 10-K annual reports. Free cash flow describes banks, real estate investment trusts and funds poorly, so treat their figures with extra caution. In the cash returned and balance sheet tables, a value of zero is treated as a gap in the data, not as a real zero.

Read the filings yourself: ALKS annual reports (10-K) on SEC EDGAR. To try your own growth rate, use the intrinsic value calculator on this page. Our editorial standards explain how Trendshare handles its sources and corrections.

Advertisement supports free stock analysis content.

Questions to Answer Before You Invest in ALKS

Does Alkermes plc have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.

Worked example: ALKS

This example shows how we apply the Trendshare checklist to ALKS: earnings power, cash generation, valuation, and margin of safety.

We check: business quality, free cash flow, P/E, and margin of safety.

  1. Step 1 — Snapshot

    • Price: 44.94
    • Market cap: $7.6B
    • EPS: -0.01
  2. Step 2 — Valuation checks

    • P/E: —
    • FCF yield: —
    • Date checked: Nov 20, 2026
  3. Step 3 — Margin of safety

    • Compare price to fair value and safety price.
    • Look for durable cash generation and reasonable leverage.
    • Decide if it passes your personal checklist.